Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system

BackgroundUpadacitinib, a Janus kinase inhibitor, has been increasingly used over the past few years to treat moderate to severe ulcerative colitis and Crohn’s disease in patients who are insufficiently responsive or intolerant to tumor necrosis factor (TNF) antibodies, demonstrating notable clinica...

Full description

Saved in:

Bibliographic Details
Main Authors:	Shiyi Wang, Xiaojian Wang, Jing Ding, Xudong Zhang, Hongmei Zhu, Yihong Fan, Changbo Sun
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Pharmacology
Subjects:	upadacitinib adverse event FAERS pharmacovigilance data mining
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1436183/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
by: Shan Lin, et al.
Published: (2024-10-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system
by: Yaqian Tan, et al.
Published: (2025-08-01)

Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study
by: Chengzhi Liu, et al.
Published: (2024-12-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qi Song, et al.
Published: (2025-06-01)

Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database
by: Xianyu Dai, et al.
Published: (2025-07-01)

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Zhuomiao Lin, et al.
Published: (2025-08-01)

Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system
by: Qian Yu, et al.
Published: (2025-08-01)

A real-world pharmacovigilance study of lorazepam based on the FDA adverse event reporting system database
by: Chunyue Fang, et al.
Published: (2025-06-01)

A real-world pharmacovigilance study of netarsudil based on the FDA adverse event reporting system (FAERS)
by: Xiaomei Xiong, et al.
Published: (2025-04-01)

Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database
by: Juan Su, et al.
Published: (2025-07-01)

Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system
by: Yunhan Zhao, et al.
Published: (2025-05-01)

Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
by: Qun Li, et al.
Published: (2025-02-01)

Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system
by: Chengyu Zhu, et al.
Published: (2025-03-01)

Disproportionality analysis and risk factor assessment of drug-associated thyroid dysfunction adverse events: a study based on the FAERS database
by: Zhifang Wang, et al.
Published: (2025-07-01)

A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system
by: Miao Liu, et al.
Published: (2025-08-01)

Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system
by: Yanjun Lu, et al.
Published: (2024-12-01)

The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yutong Wu, et al.
Published: (2025-05-01)

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01)

A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database
by: Yunlin Yang, et al.
Published: (2025-04-01)

A pharmacovigilance study on probiotic preparations based on the FDA Adverse Event Reporting System from 2005 to 2023
by: Yitong Wang, et al.
Published: (2025-05-01)

Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database
by: Zhenpo Zhang, et al.
Published: (2025-07-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab
by: Linlin Yan, et al.
Published: (2025-04-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag
by: Zhong Xue, et al.
Published: (2024-11-01)

Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database
by: Runan Fang, et al.
Published: (2024-11-01)

A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database
by: Xueping Shi, et al.
Published: (2025-04-01)

Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system
by: Sentai Wang, et al.
Published: (2025-03-01)

Exploring Novel Adverse Events of Nefecon
by: Jingyu Wang, et al.
Published: (2024-09-01)

Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System
by: He Chen, et al.
Published: (2025-05-01)

Comprehensive safety analysis of adverse events associated with eptinezumab in migraine treatment
by: Junchen Chen, et al.
Published: (2025-07-01)

Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database
by: Huiling Zhang, et al.
Published: (2025-07-01)

A real-world pharmacovigilance study of neuroleptic malignant syndrome based on FDA adverse event reporting system
by: Yu Zhang, et al.
Published: (2024-12-01)

Drug‐Related Hypertension: A Disproportionality Analysis Leveraging the FDA Adverse Event Reporting System
by: Hao Zhu, et al.
Published: (2025-03-01)

Post-marketing safety concerns with Tislelizumab: a disproportionality analysis of the FDA adverse event reporting system
by: Chen Li, et al.
Published: (2025-05-01)

Chloroquine and hydroxychloroquine-related ocular adverse events in SLE treatment: a real-world disproportionality analysis based on FDA adverse event reporting system (FAERS)
by: Xiang Li, et al.
Published: (2025-06-01)

An investigation of drug-induced mental disorders in the children and adolescents population utilizing the FDA adverse event reporting system
by: Linlin Tang, et al.
Published: (2025-07-01)

Drug-induced herpes zoster: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024
by: Jiali Xia, et al.
Published: (2025-03-01)

Drug-associated hearing impairment in children: a disproportionality analysis of the FDA adverse event reporting system
by: Jinfeng Liu, et al.
Published: (2025-06-01)